Use the Back button in your browser to see the other results of your search or to select another record.
| Effects of attentional bias modification on chronic low back pain in older outpatients: a randomized crossover trial (pilot study) |
| Hasegawa T, Nishi K, Nakashima A, Moriuchi T, Iso N, Koseki H, Tabira T, Higashi T |
| Medicine 2021 Nov 12;100(45):e27738 |
| clinical trial |
| 5/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed* |
|
OBJECTIVES: In the present study, the effect of attentional bias modification (ABM) on older outpatients, with chronic low back pain, was examined. DESIGN: This was a single-center, randomized, single-blinded, crossover trial and patients were randomly divided in a 1:1 allocation ratio into two groups: an ABM Leading group and an ABM Trailing group. PARTICIPANTS: Forty-three outpatients with chronic low back pain participated. INTERVENTIONS: Patients were evaluated four times and the treatments were ABM plus normal intervention or normal intervention only. OUTCOMES: Outcome measures included pain intensity on the Numerical Rating Scale, the Pain Catastrophizing Scale, Fear-Avoidance Beliefs Questionnaire, Hospital Anxiety and Depression Scale, Somatic Symptom Scale-8, and EuroQol 5 Dimension-3 levels questionnaire. In addition, we performed the 30-second Chair-Stand Test and the Timed Up and Go Test for physical function evaluations. RESULTS: There was no change in pain intensity due to ABM. However, the total Pain Catastrophizing Scale score was significantly decreased, and the EuroQol 5 Dimension-3 levels questionnaire and 30-second Chair-Stand Test were significantly improved (p < 0.05). TRIAL REGISTRATION: The Health Science Ethics Committee, Graduate School of Biomedical Sciences, Nagasaki University (permit number 17060861), and the clinical trial was registered (UMIN000029424).
|